Seres Therapeutics Inc (MCRB) - Total Liabilities
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has total liabilities worth $67.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Seres Therapeutics Inc (MCRB) long-term investment share to see how much of total assets are deployed in long-term investments.
Seres Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Seres Therapeutics Inc assets under control.
Seres Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Seres Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Very Good Tour Co. Ltd
KQ:094850
|
Korea | ₩67.54 Billion |
|
Sumi Indo Kabel Tbk
JK:IKBI
|
Indonesia | Rp25.31 Million |
|
Uangel
KO:072130
|
Korea | ₩12.65 Billion |
|
JP Morgan Global Growth & Income PLC
LSE:JGGI
|
UK | GBX151.54 Million |
|
UNIQUE
KLSE:0257
|
Malaysia | RM31.90 Million |
|
Universal Textile Co Ltd
TW:1445
|
Taiwan | NT$2.38 Billion |
|
LORDS CHLORO ALKALI ORD T (BSE)
NSE:LORDSCHLO
|
India | Rs2.36 Billion |
|
Honmyue Enterprise Co Ltd
TW:1474
|
Taiwan | NT$1.54 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Seres Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Seres Therapeutics Inc (MCRB) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seres Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seres Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Seres Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $93.97 Million | -25.43% |
| 2024-12-31 | $126.03 Million | -68.76% |
| 2023-12-31 | $403.46 Million | +19.37% |
| 2022-12-31 | $338.00 Million | +51.33% |
| 2021-12-31 | $223.35 Million | +32.80% |
| 2020-12-31 | $168.19 Million | -6.96% |
| 2019-12-31 | $180.76 Million | +7.27% |
| 2018-12-31 | $168.52 Million | +30.81% |
| 2017-12-31 | $128.82 Million | -7.99% |
| 2016-12-31 | $140.01 Million | +1116.89% |
| 2015-12-31 | $11.51 Million | -92.01% |
| 2014-12-31 | $144.07 Million | +9542.97% |
| 2013-12-31 | $1.49 Million | +739.33% |
| 2012-12-31 | $178.00K | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more